Guardant Health enters the back half of May with short sellers quietly backing away and analysts nudging targets higher — a combination that frames a more constructive backdrop heading into the June 17 Q1 results.
Short interest has been on a steady downward path over the past month. It now runs at roughly 9.4% of the free float — meaningful, but down from a mid-April peak above 11.5% when around 14.7 million shares were short. That's a drop of more than 2 million shares, or about 16%, in the space of four weeks. The retreat has been orderly rather than a sharp cover, suggesting shorts are scaling back on thesis changes rather than getting squeezed out.
The borrow market reinforces that picture. Cost to borrow has dropped sharply, falling 25% on the week to 0.30% — the lowest level in the 30-day window and down more than 40% on the month. Availability is exceptionally loose at 1,391% of the outstanding short interest, up from around 940% a week ago, meaning there is no friction in the lending market for anyone wanting to build a new position either way. Options positioning has also shifted. The put/call ratio edged up to 0.82 on Monday and Tuesday from a range closer to 0.61–0.64 through most of last week, though the z-score remains a modest 0.30 — well within normal territory and far below the hedged reading above 1.2 that marked options sentiment in mid-April. The overall message from positioning is that bears are retreating without a rush, and options traders have relaxed their defensive stance considerably.
The Street has grown more constructive in the wake of the May 7 earnings print. JP Morgan lifted its target from $130 to $135 while holding Overweight, and Barclays moved from $115 to $120 on the same day, maintaining the same constructive rating. Both moves came directly after the quarterly release, which saw the stock gain 3.7% on the day and nearly 7% over the following five sessions. Sixteen buy-rated analysts now cover the name against no reported sells, with a consensus mean target of $130.52 — implying roughly 33% upside from the current $98.19. Evercore ISI sits as the outlier, maintaining an In-Line rating with a $95 target, citing reimbursement dynamics as the key overhang. The bull case centres on Guardant's dominant position in the liquid biopsy market — over 50% share in circulating genomic profiling, with nearly 30% year-on-year volume growth — and the potential for higher average selling prices as new reimbursement categories come online. The bear case is narrower but sharp: pending PAMA regulations could deliver a one-time revenue reduction in the region of $100 million, and multi-cancer early detection reimbursement timelines remain uncertain. Valuation multiples are largely uninformative at this stage given the company is still loss-making, with a negative PE of -88 and a deeply negative book value, but the earnings-per-share forward trajectory stands in the 99th percentile for year-on-year improvement — a signal that the Street expects the gap to close.
Institutional ownership adds a layer of interest. T. Rowe Price added over 2.1 million shares in the most recent quarter to reach 5.9% of shares outstanding, making it one of the larger incremental buyers. Two Sigma also added more than 2 million shares in the same period. The insider picture is more mixed. CEO Amirali Talasaz sold 50,000 shares at $100.32 on May 12 for proceeds of roughly $5 million, the largest individual sale in the recent window. CTO Darya Chudova sold a further 4,679 shares on May 15 concurrent with receiving an equity award of 8,705 shares — a net positive in share terms but flagging open-market sales near recent highs. The 90-day insider net is positive at just over 91,000 shares, though the dollar value of net activity ($8.8 million) is dominated by earlier award-driven flows. These are not alarm-signal trades, but the CEO sale at the top of the three-month range is worth noting.
The two most recent earnings reactions both moved higher — up 3.7% and 5.0% respectively on the day of release, extending to 7% and 10.6% over the subsequent five sessions. The next print is scheduled for June 17. With short interest down, borrow costs falling, and the analyst community freshly lifting targets, the setup heading into that date is markedly less defensive than it was a month ago.
See the live data behind this article on ORTEX.
Open GH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
